KR20230086713A - 안구 질환의 치료를 위한 방법 및 제제 - Google Patents

안구 질환의 치료를 위한 방법 및 제제 Download PDF

Info

Publication number
KR20230086713A
KR20230086713A KR1020237015441A KR20237015441A KR20230086713A KR 20230086713 A KR20230086713 A KR 20230086713A KR 1020237015441 A KR1020237015441 A KR 1020237015441A KR 20237015441 A KR20237015441 A KR 20237015441A KR 20230086713 A KR20230086713 A KR 20230086713A
Authority
KR
South Korea
Prior art keywords
seq
sequence
antibody
cdr1
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237015441A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 지겔라
게리 레드리치
Original Assignee
라인 식스 바이오테크놀로지, 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020903624A external-priority patent/AU2020903624A0/en
Application filed by 라인 식스 바이오테크놀로지, 인크 filed Critical 라인 식스 바이오테크놀로지, 인크
Publication of KR20230086713A publication Critical patent/KR20230086713A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020237015441A 2020-10-07 2021-10-07 안구 질환의 치료를 위한 방법 및 제제 Pending KR20230086713A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020903624 2020-10-07
AU2020903624A AU2020903624A0 (en) 2020-10-07 Methods and agents for the treatment of ocular disease
PCT/AU2021/051173 WO2022073072A1 (en) 2020-10-07 2021-10-07 Methods and agents for the treatment of ocular disease

Publications (1)

Publication Number Publication Date
KR20230086713A true KR20230086713A (ko) 2023-06-15

Family

ID=81127099

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015441A Pending KR20230086713A (ko) 2020-10-07 2021-10-07 안구 질환의 치료를 위한 방법 및 제제

Country Status (8)

Country Link
US (3) US11618782B2 (https=)
EP (1) EP4225796A4 (https=)
JP (1) JP2023545579A (https=)
KR (1) KR20230086713A (https=)
CN (1) CN116710135A (https=)
AU (1) AU2021356298A1 (https=)
IL (1) IL301762A (https=)
WO (1) WO2022073072A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
AU2021356298A1 (en) 2020-10-07 2023-05-04 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820858A (en) 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
AU2001290315A1 (en) 2000-11-22 2002-06-03 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
WO2006063292A1 (en) * 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
US20060257411A1 (en) * 2005-05-06 2006-11-16 Bruce Beutler Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway
WO2009002790A2 (en) * 2007-06-26 2008-12-31 Bausch & Lomb Incorporated Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye
WO2009089401A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same
PT3065761T (pt) * 2013-11-05 2020-02-21 Allergan Inc Método de tratamento de condições oculares com um darpin anti-vegf
AU2014370404A1 (en) * 2013-12-24 2016-07-07 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
US20160038589A1 (en) * 2014-08-11 2016-02-11 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
US10407510B2 (en) * 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
IL309046B2 (en) * 2017-04-21 2025-03-01 Implicit Bioscience Ltd CD14 antagonist antibodies for the treatment of neurodegenerative diseases
KR20190059164A (ko) * 2017-11-22 2019-05-30 건국대학교 글로컬산학협력단 가용성 cd14의 당뇨황반부종 진단 및 치료 용도
AU2021356298A1 (en) 2020-10-07 2023-05-04 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease

Also Published As

Publication number Publication date
AU2021356298A1 (en) 2023-05-04
JP2023545579A (ja) 2023-10-30
US20220220194A1 (en) 2022-07-14
CN116710135A (zh) 2023-09-05
AU2021356298A9 (en) 2024-04-18
US20240002489A1 (en) 2024-01-04
IL301762A (en) 2023-05-01
US12258390B2 (en) 2025-03-25
WO2022073072A1 (en) 2022-04-14
US11618782B2 (en) 2023-04-04
EP4225796A4 (en) 2024-11-13
US20250230228A1 (en) 2025-07-17
EP4225796A1 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
JP7775347B2 (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
US12258390B2 (en) Methods and agents for the treatment of ocular disease
JP2021112204A (ja) ＴＧＦ−βに特異的な抗体
CN113544151B (zh) 抗il-27抗体及其用途
TW201417829A (zh) 預防及治療與補體相關之眼部病症
KR20230005848A (ko) 항-trem2 항체의 사용 방법
CN107106681B (zh) 治疗或预防中风的方法
KR20210114964A (ko) 화농성 한선염 치료에 사용하기 위한 항-cd40 항체
CA2665956A1 (en) Combination treatment for ocular diseases
JP2018530574A (ja) 患者の加齢黄斑変性を治療する方法
WO2022011323A1 (en) Ocular disease treatment using anti-tissue factor antibodies
US20250276059A1 (en) Therapeutic methods and agents for the treatment of myocardial infarction
KR20220040478A (ko) 급성 신경염증성 손상을 치료하기 위한 방법 및 제제
CN119630698A (zh) 血管生成素相关蛋白7特异性抗体及其用途
KR20250093319A (ko) Il-6 길항제에 대한 반응 예측
US20200239562A1 (en) Anti-il-33 therapy for atopic dermatitis
NZ735964B2 (en) Antibodies Specific For TGF-Beta

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230504

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241004

Comment text: Request for Examination of Application